UCB inject patient confidence

UCB has announced that the new certolizumab pegol (Cimzia®) AutoClicks® Prefilled Pen is now available on the NHS, following the recent positive opinion by the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

The EMA’s CHMP decision recommended the use of the pen in all approved indications (rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis [AS] and axial spondyloarthritis [axSpA]). The positive opinion was based on validated data and risk benefit analysis.

Meanwhile, UCB is continuing its partnership with OXO – a company known for consumer-friendly designs – to develop the AutoClicks® Prefilled Pen, based on core technology licensed from Bespak. The pen provides a button-free delivery system, a wide non-slip grip and a large viewing window that shows the progress of an injection.

Dr Ravik Mascarenhas, Consultant Rheumatologist at the Royal Devon & Exeter Foundation Trust, said, “I see many patients whose joints have been destroyed by this painful disease, so having a new choice is welcomed. Like most of us they also tend to find it a challenge self-injecting because of a needle – with this new pre-filled pen the patient doesn’t even see the needle which may take some of the nerves and fear away.”